UCB Links With Daiichi Sankyo For Epilepsy In Japan
This article was originally published in PharmAsia News
UCB has chosen Daiichi Sankyo as its new commercial partner in Japan for an epilepsy drug, building on an existing relationship in the allergy area.
You may also be interested in...
In this week's podcast edition of Five Must-Know Things: CAR-Ts and malignancies; comeback for GSK’s Blenrep?; Novartis’s pipeline cull; FGF21 analogs in NASH; and a call to action from the Scrip Awards Lifetime Achievement winner.
In this week's podcast edition of Five Must-Know Things: Bayer’s Phase III failure; US group seeks Japan changes; AstraZeneca winning AKT race for now; NASH developments at AASLD; and the Q3 impact of China’s corruption campaign.
In this week's podcast edition of Five Must-Know Things: AstraZeneca CEO on obesity and more; biotech’s rollercoaster ride set to continue; new Wegovy data; Novo’s plans for semaglutide in NASH; and Zepbound set to become biggest drug ever?